Savara Inc.'s stock (NASDAQ:SVRA) plummeted 75.2% Thursday as top-line data from Impala, the phase III trial of Molgradex, showed the study failed to meet its primary endpoint in rare lung disease autoimmune pulmonary alveolar proteinosis. Read More
Blackthorn Therapeutics Inc., a San Francisco-based company seeking traction for a high-tech approach to targeted mental health therapy, has closed a $76 million series B financing expected to help carry a mood disorder program into phase II later this year and move an autism-focused asset into the clinic. Both new and previous investors backed the round. Read More
BOGOTA, Colombia – As a first step to reach out to international markets, Mannkind Corp., of Westlake Village, Calif., has received a green light to market Afrezza, its insulin inhalation powder, in Brazil. Read More
PHILADELPHIA – Along with the opportunity to hear about the latest science and business developments taking place, delegates attending the BIO 2019 meeting were provided with an update on the state-of-the industry in the U.S. During the event several reports were released that clearly demonstrate biotechnology has become a major economic driver not only for the country, but individual states as well, particularly those that have actively engaged in building and supporting a bioscience infrastructure. Read More
HONG KONG – The complexity of interactions between the interleukin-17 (IL-17) family of receptors and ligands has been elucidated in a Chinese study, which may lead to development of specific targeting strategies for treating IL-17-related autoimmune inflammatory diseases, notably psoriasis. Read More
HONG KONG – Swedish biopharma Calliditas Therapeutics AB and Singapore-headquartered pharmaceutical company Everest Medicines II Ltd. agreed to develop and commercialize Nefecon for the treatment of IgA nephropathy in greater China and Singapore in a deal valued at more than $121 million. Read More
Arcturus Therapeutics Holdings Inc., of San Diego, obtained approval from the Israeli court to complete the re-domiciliation process to the U.S. as a Delaware corporation, which was approved by the company's shareholders on May 17. Read More
Seres Therapeutics Inc., of Cambridge, Mass., commenced an underwritten registered public offering of $60 million of shares of its common stock. Seres intends to grant the underwriters a 30-day option to purchase up to an additional $9 million of shares. Goldman Sachs & Co. LLC and Cowen and Co. LLC are acting as joint book-running managers. Read More
